Does UPMC Health Plan Cover Eliquis?

How UPMC Health Plan Classifies Eliquis on Its Formulary

Most UPMC Health Plan products place Eliquis (apixaban) on their preferred-brand tier, which is typically Tier 3 in a four- or five-tier formulary structure. This applies across commercial HMO, PPO, and EPO options as well as UPMC for Life Medicare Advantage plans.

Formulary tier placement determines what percentage of the drug's cost a member pays after the deductible. For a Tier 3 preferred brand under a standard UPMC commercial plan, the typical copay falls between $35 and $75 per 30-day supply. UPMC for Life Medicare Advantage members may see slightly different cost-sharing based on the coverage phase they occupy (deductible, initial coverage, or catastrophic). The FDA's approval of apixaban for multiple indications means UPMC covers it for atrial fibrillation-related stroke prevention, deep vein thrombosis (DVT) treatment, pulmonary embolism (PE) treatment, and post-surgical thromboprophylaxis following hip or knee replacement.

UPMC publishes its formulary lists online and updates them quarterly. Members should verify the most current tier placement through the UPMC Health Plan member portal or by calling the number on their insurance card. A drug's tier can shift between formulary updates, particularly when new generics enter the market or when the plan renegotiates rebate agreements with manufacturers.

What Eliquis Costs Under Different UPMC Plans

The actual dollar amount a UPMC member pays for Eliquis depends on several variables: plan type, deductible status, whether the pharmacy is in-network, and whether the member uses mail-order.

Under UPMC commercial plans with a standard three-tier copay structure, members typically pay $45 to $75 per month for a 30-day supply of Eliquis 5 mg twice daily. High-deductible health plans (HDHPs) paired with HSAs require the member to pay the full negotiated price until the deductible is met, which can mean $500 or more per month before cost-sharing kicks in. UPMC for Life Medicare Advantage plans follow Part D cost-sharing rules, where members in the initial coverage phase may pay 25% of the drug cost after reaching the deductible. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D, fully effective since 2025, provides meaningful protection for members taking high-cost brand-name anticoagulants like Eliquis.

Mail-order through UPMC Health Plan's preferred pharmacy benefit manager often reduces per-unit costs. A 90-day mail-order supply typically costs the equivalent of two monthly copays rather than three, saving the member roughly 33% over a calendar year. For a drug taken indefinitely (as most anticoagulants are), this adds up. A member paying $60/month at retail would pay approximately $120 for a 90-day mail supply, saving $240 annually.

Bristol-Myers Squibb's Eliquis copay assistance card can reduce the monthly out-of-pocket cost to as low as $10 for commercially insured members. This card does not apply to government-funded insurance including Medicare, Medicaid, or Tricare. The manufacturer's program has annual savings limits, so members should confirm current terms before relying on it as a long-term cost strategy.

Prior Authorization and Step Therapy Requirements

UPMC Health Plan may require prior authorization for Eliquis depending on the specific plan and the clinical indication. For the most common use (stroke prevention in nonvalvular atrial fibrillation), many UPMC plans approve Eliquis without prior authorization because clinical guidelines from the American Heart Association and American College of Cardiology recommend direct oral anticoagulants as first-line therapy over warfarin.

The 2019 AHA/ACC/HRS Focused Update on atrial fibrillation management states that DOACs are recommended over warfarin in eligible patients with nonvalvular AF (Class I recommendation). This guideline support makes it difficult for insurers to deny coverage for the AF indication without medical justification.

Step therapy is different from prior authorization. Some UPMC plans, particularly lower-premium options, require documentation that a patient has tried or has a contraindication to warfarin before the plan will approve a DOAC. This is less common than it was five years ago, but it still appears on certain formulary designs. If a prescriber believes step therapy is clinically inappropriate (for example, a patient with poor INR control history, dietary restrictions that make warfarin impractical, or a high HAS-BLED score), they can submit a step therapy exception request.

The prescriber typically needs to provide clinical notes documenting why warfarin is unsuitable. UPMC Health Plan must respond to standard prior authorization requests within 72 hours and urgent requests within 24 hours under Pennsylvania insurance regulations.

Why Physicians Prescribe Eliquis Over Warfarin

The clinical evidence favoring apixaban over warfarin is substantial. The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced the rate of stroke or systemic embolism by 21% compared to warfarin (1.27% vs. 1.60% per year, p=0.01 for superiority) while also reducing major bleeding by 31% (2.13% vs. 3.09% per year, p<0.001) and all-cause mortality by 11% (3.52% vs. 3.94%, p=0.047) in patients with nonvalvular atrial fibrillation [1].

These are not marginal differences. Fewer strokes, less bleeding, and lower mortality in a single trial is unusual for any drug comparison. The ARISTOTLE results published in the New England Journal of Medicine led to a rapid shift in prescribing patterns. By 2023, DOACs accounted for over 80% of new oral anticoagulant prescriptions in the United States [2].

For venous thromboembolism, the AMPLIFY trial (N=5,395) showed apixaban was noninferior to conventional therapy (enoxaparin followed by warfarin) for recurrent VTE (2.3% vs. 2.7%) while causing significantly less major bleeding (0.6% vs. 1.8%, p<0.001) [3]. This dual advantage across both AF and VTE indications is why Eliquis has become the most prescribed anticoagulant in the country.

Dr. John Mandrola, a cardiac electrophysiologist, has noted: "The data supporting DOACs over warfarin in nonvalvular AF is about as clear as it gets in cardiology. The bleeding advantage of apixaban specifically makes it hard to justify warfarin as a first choice for most patients."

The Endocrine Society's clinical practice guidelines and the American College of Cardiology's expert consensus documents both support DOAC use as preferred first-line anticoagulation for eligible patients with AF.

Generic Apixaban: How It Affects UPMC Coverage

The FDA approved the first generic versions of apixaban in late 2024, and multiple manufacturers have since launched generic products. This has significant implications for UPMC Health Plan members.

Generic apixaban is rated AB-equivalent to brand Eliquis, meaning the FDA considers it therapeutically interchangeable. UPMC Health Plan has begun moving generic apixaban to lower formulary tiers (typically Tier 2 or even Tier 1 on some plans), which can reduce monthly copays to $10 to $25. Some UPMC plans have implemented mandatory generic substitution, meaning pharmacies will automatically dispense generic apixaban unless the prescriber writes "brand medically necessary" and the plan approves the exception.

For members currently taking brand Eliquis, the transition to generic is straightforward. The active ingredient, dose, and administration schedule are identical. There is no clinical reason to avoid the switch. A Cochrane review of generic cardiovascular drug substitution found no significant differences in clinical outcomes between brand-name and generic cardiovascular medications across 47 studies.

The price impact is already visible. Cash prices for generic apixaban have dropped to approximately $30 to $80 per month at many pharmacies, compared to the brand-name wholesale acquisition cost of approximately $580 per month. For UPMC members with high-deductible plans who pay full price until their deductible is met, the generic represents a reduction of 85% or more in out-of-pocket spending during the deductible phase.

How to Check Your Specific UPMC Plan's Coverage

The most reliable way to confirm Eliquis coverage under your UPMC plan is a three-step process.

First, log into the UPMC Health Plan member portal and manage to the formulary search tool. Enter "apixaban" or "Eliquis" to see the tier placement, any quantity limits, and whether prior authorization is required for your specific plan. Second, call the member services number on your insurance card and ask specifically: "Is Eliquis covered on my plan's formulary, and what is my estimated copay?" Representatives can provide a cost estimate based on your plan's benefit design, deductible status, and preferred pharmacy network. Third, ask your pharmacist to run a test claim. This generates the most accurate cost estimate because it reflects your real-time deductible accumulation, any copay card savings, and network-specific pricing.

UPMC operates its own pharmacy network through UPMC Pharmacy, which may offer preferred pricing for members who fill prescriptions at UPMC-owned pharmacies compared to out-of-network retail chains. This is especially relevant for members in the Pittsburgh metropolitan area where UPMC pharmacy locations are concentrated.

If you discover that Eliquis is not covered or is on a non-preferred tier, your prescriber can submit a formulary exception request. The American Heart Association's patient resources recommend that patients work with their cardiologist's office to manage insurance authorization processes, as clinical staff are experienced with documenting medical necessity for anticoagulants.

What to Do If UPMC Denies Eliquis Coverage

Coverage denials happen. They are not always the final answer. UPMC Health Plan members have a structured appeals process, and success rates for anticoagulant appeals tend to be higher than for many other drug classes because the clinical evidence supporting DOACs is strong.

The first step is to request the denial in writing, which UPMC is required to provide. The denial letter must state the specific reason (formulary exclusion, prior authorization not met, step therapy requirement, or quantity limit exceeded). Your prescriber then submits a peer-to-peer review or written appeal with supporting clinical documentation.

Strong appeal arguments for Eliquis coverage include: documented warfarin intolerance or allergy, inability to maintain therapeutic INR despite compliance, high fall risk where the bleeding profile of apixaban (demonstrated in ARISTOTLE to be superior to warfarin [1]) provides a meaningful safety advantage, and dietary or drug interactions that make warfarin management unreliable.

Under Pennsylvania Act 68 (the Quality Health Care Accountability and Protection Act), UPMC Health Plan members have the right to an external review by an independent third party if internal appeals are exhausted. The CDC's guidance on anticoagulation therapy notes that adherence to anticoagulant therapy is closely tied to patient access and affordability, making coverage decisions clinically consequential.

If the appeal is for a Medicare Advantage member, CMS rules require UPMC for Life to process coverage determination requests within 72 hours for standard requests and 24 hours for expedited requests. Medicare Part D also allows any beneficiary to request a coverage determination and appeal a denial through five levels of review.

Patient Assistance Programs Beyond Insurance

Even with UPMC Health Plan coverage, some members may find Eliquis copays burdensome. Several programs exist to reduce costs.

The Bristol-Myers Squibb/Pfizer Eliquis 360 Support Program provides free medication to qualifying uninsured or underinsured patients. Income thresholds apply, typically at or below 400% of the federal poverty level. For 2026, that threshold is approximately $62,400 for a single individual. The program also offers a copay assistance card for commercially insured patients, reducing copays to as low as $10 per fill.

State pharmaceutical assistance programs (SPAPs) in Pennsylvania, such as PACE and PACENET, serve residents aged 65 and older with limited income. These programs coordinate with Medicare Part D to reduce cost-sharing on covered medications. PACE covers copays of $6 for generic drugs and $9 for brand-name drugs for qualifying individuals with income up to $14,500 (single) or $17,700 (married) [4].

The National Institutes of Health maintains a database of clinical trials that may provide access to anticoagulant therapy at no cost for eligible participants. Members interested in this option should discuss it with their prescriber, as trial participation involves specific eligibility criteria and monitoring requirements.

For members with UPMC for Life Medicare Advantage, the Medicare Part D Low-Income Subsidy (Extra Help) program can reduce premiums, deductibles, and copays significantly. Those who qualify for full Extra Help pay no more than $4.50 for generic drugs and $11.20 for brand-name drugs per prescription in 2026.

Comparing Eliquis to Other Anticoagulants Covered by UPMC

UPMC Health Plan covers multiple anticoagulants, and formulary position varies by drug. Understanding the options helps members and prescribers make informed choices when cost is a factor.

Warfarin (generic) sits on the lowest tier (Tier 1) of virtually every UPMC formulary, with copays of $0 to $15 per month. It requires regular INR monitoring, dietary consistency, and carries a higher major bleeding risk than apixaban based on ARISTOTLE data [1]. A JAMA Network meta-analysis of four major DOAC trials found that apixaban had the most favorable bleeding profile among all DOACs compared to warfarin [5].

Rivaroxaban (Xarelto) is typically on the same tier as Eliquis on UPMC formularies. The ROCKET-AF trial (N=14,264) showed rivaroxaban was noninferior to warfarin for stroke prevention but did not demonstrate superiority for either efficacy or bleeding endpoints [6]. Apixaban's superiority on both counts in ARISTOTLE makes it the preferred DOAC in most clinical guidelines.

Dabigatran (Pradaxa) is often placed on a preferred brand tier as well. The RE-LY trial (N=18,113) showed the 150 mg dose reduced stroke compared to warfarin but with similar major bleeding rates [7]. Dabigatran requires twice-daily dosing (like apixaban) but has higher rates of GI side effects.

Edoxaban (Savaysa) is less commonly prescribed and may be on a higher (non-preferred) tier on some UPMC formularies. It is dosed once daily, which some patients prefer, but has a narrower therapeutic window and a paradoxical dose-response in patients with high creatinine clearance.

Generic apixaban now provides UPMC members a lower-cost option that maintains the efficacy and safety profile of brand Eliquis. For patients specifically asking about cost savings, generic apixaban or warfarin (when clinically appropriate) represent the most affordable paths on UPMC formularies.